<DOC>
	<DOCNO>NCT01252953</DOCNO>
	<brief_summary>The Randomized EValuation Effects Anacetrapib Through Lipid-modification ( REVEAL ) trial aim determine whether lipid modification anacetrapib 100mg daily reduces risk coronary death , myocardial infarction ( MI ) coronary revascularization ( collectively know major coronary event ) patient circulatory problem Low-density Lipoprotein ( LDL ) cholesterol level treat statin .</brief_summary>
	<brief_title>REVEAL : Randomized EValuation Effects Anacetrapib Through Lipid-modification</brief_title>
	<detailed_description>Sub-study : Does anacetrapib CETP inhibitor lead mobilization stem cell enhance myocardial function via neoangiogenesis tissue regeneration ? Following main on-treatment part study , period least 2 year participant followed-up telephone , treatment .</detailed_description>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Anacetrapib</mesh_term>
	<mesh_term>Oxazolidinones</mesh_term>
	<criteria>Patients must age least 50 time initial invitation , least one follow inclusion criterion must satisfy : History MI ; Cerebrovascular atherosclerotic disease ( i.e . history presumed ischaemic stroke carotid revascularization ) ; Peripheral arterial disease ( i.e . history noncoronary revascularization , include aortic aneurysm repair graft ) ; Diabetes mellitus evidence symptomatic coronary heart disease ( i.e . treatment hospitalization angina , history coronary revascularization acute coronary syndrome ) . None follow must satisfy : Acute MI , acute coronary syndrome stroke within 4 week prior Screening Visit Runin ( individual may enter later , appropriate ) ; Planned coronary revascularization procedure within next 6 month ( individual may enter later , appropriate ) ; Definite history chronic liver disease , abnormal liver function ( i.e . alanine transaminase ( ALT ) &gt; 2x upper limit normal ( ULN ) ) . Note : Individuals history acute hepatitis eligible provide ALT limit exceed ; Severe renal insufficiency ( i.e . creatinine &gt; 200 Âµmol/L [ 2.3 mg/dL ] , dialysis function renal transplant ) ; Evidence active inflammatory muscle disease ( e.g . dermatomyositis , polymyositis ) , creatine kinase ( CK ) &gt; 3x ULN ; Previous significant adverse reaction statin anacetrapib ; Current treatment follow lipidlowering treatment : ( ) regimen consider produce substantially great LDL cholesterol reduction atorvastatin 80 mg daily individual nonAsian country 20 mg daily North East Asia ; ( ii ) fibric acid derivative ( `` fibrate '' , include gemfibrozil ) ; ( iii ) niacin ( nicotinic acid ) dose 100 mg daily Concurrent treatment medication contraindicate anacetrapib atorvastatin : ( ) potent CYP3A4 inhibitor , : 1. macrolide antibiotic ( erythromycin , clarithromycin , telithromycin ) ; 2. systemic imidazole triazole antifungal ( e.g . itraconazole , posaconazole ) ; 3. protease inhibitor ( e.g . atazanavir ) ; 4. nefazodone ( ii ) ciclosporin ( iii ) daptomycin ( iv ) systemic use fusidic acid Note : Individuals take drug temporarily may rescreened discontinue , consider appropriate ; Known poorly compliant clinic visit prescribe medication ; Medical history might limit individual 's ability take trial treatment duration study ( e.g . severe respiratory disease ; history cancer evidence spread within last 5 year , nonmelanoma skin cancer ; recent history alcohol substance misuse ) ; Women childbearing potential ( unless use adequate contraception ) ; Current participation clinical trial unlicensed drug device . Individuals also exclude Screening visit consider unlikely achieve total cholesterol &lt; 3.5 mmol/L ( 135 mg/dL ) high atorvastatin dose available region ( atorvastatin 80 mg daily nonAsian country 20 mg daily North East Asia ) . In addition , individual exclude Randomization visit follow true : Total cholesterol 4 mmol/L [ 155 mg/dL ] Noncompliant runin treatment ( &lt; 90 % schedule runin medication take ) Individual longer willing randomize 45 year trial The individual 's doctor view patient randomize .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>vascular disease</keyword>
	<keyword>lipid</keyword>
	<keyword>cholesteryl ester transfer protein ( CETP ) inhibition</keyword>
	<keyword>anacetrapib</keyword>
</DOC>